Stefano Del Prato

List of PR Articles by Year in descending order

356 PR articles	29,404 PR citations	6343 70 PR h-index	3261 166 g-index
390 documents	34029 doc citations	6261 76 h-index	38560 citing authors

#	Article	IF	PR Citations
1	Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis. Circulation: Heart Failure, 2025, 18, .	5.5	3
2	Cardioâ€renalâ€metabolic disease in primary care setting. Diabetes/Metabolism Research and Reviews, 2024, 40, .	5.2	8
3	Cardiovascular and renal outcomes with varying degrees of kidney disease in highâ€risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDEâ€O trial. Diabetes, Obesity and Metabolism, 2024, 26, 1216-1223.	4.7	2
4	Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nature Reviews Endocrinology, 2024, 20, 426-440.	34.6	66
5	The current landscape for diabetes treatment: Preventing diabetes-associated CV risk. Atherosclerosis, 2024, 394, 117560.	1.6	11
6	Î²-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes Care, 2024, 47, 1131-1139.	10.1	0
7	The role of incretin receptor agonists in the treatment of obesity. Diabetes, Obesity and Metabolism, 2024, 26, 4178-4196.	4.7	13
8	Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care. Diabetologia, 2024, 67, 2585-2597.	8.2	17
9	Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. New England Journal of Medicine, 2024, 391, 2201-2211.	44.0	41
10	Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. Circulation, 2023, 147, 1004-1013.	25.3	22
11	Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia, 2023, 66, 1820-1831.	8.2	22
12	Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1â€“4 Trials. Diabetes Care, 2023, 46, 1986-1992.	10.1	30
13	MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance.. Diabetes and Metabolism, 2022, 48, 101292.	3.6	9
14	Basal weekly insulins: the way of the future!. Metabolism: Clinical and Experimental, 2022, 126, 154924.	9.5	50
15	The incretin/glucagon system as a target for pharmacotherapy of obesity. Obesity Reviews, 2022, 23, .	7.9	57
16	Challenges and opportunities in realâ€world evidence on the renal effects of sodiumâ€glucose cotransporterâ€2 inhibitors. Diabetes, Obesity and Metabolism, 2022, 24, 177-186.	4.7	18
17	A few clinical features improve the prediction of mortality and cardiovascular outcomes in patients with type 2 diabetes. European Journal of Preventive Cardiology, 2022, 28, e1-e3.	2.1	0
18	Insulin discovery: A pivotal point in medical history. Metabolism: Clinical and Experimental, 2022, 127, 154941.	9.5	24

#	Article	IF	PR Citations
19	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation, 2022, 145, 565-574.	25.3	113
20	SIRT1 rs7896005 polymorphism affects major vascular outcomes, not allâ€cause mortality, in Caucasians with type 2 diabetes: A 13â€year observational study. Diabetes/Metabolism Research and Reviews, 2022, 38, .	5.2	10
21	The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. Nature Communications, 2022, 13, .	13.9	45
22	Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report. Frontiers in Endocrinology, 2022, 13, .	4.1	4
23	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy, 2022, 13, 847-872.	2.2	18
24	Insulin secretion and action affect glucose variability in the early stages of glucose intolerance. Diabetes/Metabolism Research and Reviews, 2022, 38, .	5.2	15
25	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia, 2022, 65, 1251-1261.	8.2	211
26	Short sleep duration and risk of gestational diabetes. Gynecological Endocrinology, 2022, 38, 672-675.	1.9	6
27	Brain effect of bariatric surgery in people with obesity. International Journal of Obesity, 2022, 46, 1671-1677.	3.2	17
28	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2022, 45, 2753-2786.	10.1	1,372
29	Exercise during pregnancy: how much active are pregnant women at risk of gestational diabetes despite few contraindications?. Gynecological Endocrinology, 2021, 37, 101-104.	1.9	8
30	Design and baseline characteristics of the <scp>AMPLITUDEâ€O</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagonâ€like peptideâ€1 receptor agonist. Diabetes, Obesity and Metabolism, 2021, 23, 318-323.	4.7	18
31	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. European Psychiatry, 2021, 64, .	0.3	24
32	Predictors of post-traumatic complication of mild brain injury in anticoagulated patients: DOACs areÂsafer than VKAs. Internal and Emergency Medicine, 2021, 16, 1061-1070.	3.2	27
33	Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?. Diabetes Care, 2021, 44, 647-654.	10.1	45
34	Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes. Advances in Therapy, 2021, 38, 1715-1731.	3.5	8
35	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes Care, 2021, 44, 1062-1069.	10.1	52
36	Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139â€“e141. Diabetes Care, 2021, 44, e81-e81.	10.1	3

#	Article	IF	PR Citations
37	Impact of COVID-19 lockdown on glucose control of elderly people with type 2 diabetes in Italy. Diabetes Research and Clinical Practice, 2021, 174, 108750.	6.2	34
38	From glucose lowering agents to disease/diabetes modifying drugs: a â€œSIMPLEâ€•approach for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, .	9.9	44
39	Diabetes and acute bacterial skin and skin structure infections. Diabetes Research and Clinical Practice, 2021, 174, 108732.	6.2	44
40	Risk factors associated with postpartum impaired glucose regulation in women with previous gestational diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107854.	2.6	11
41	Bariatric surgery restores visual cortical plasticity in nondiabetic subjects with obesity. International Journal of Obesity, 2021, 45, 1821-1829.	3.2	9
42	Switching to <scp>iGlarLixi</scp> versus continuation of a daily or weekly glucagonâ€like peptideâ€1 receptor agonist (<scp>GLP</scp>â€1 <scp>RA</scp>) in insufficiently controlled type 2 diabetes: A <scp>LixiLanâ€G</scp> trial subgroup analysis by HbA1c and <scp>GLP</scp>â€1 <scp>RA</scp> use at screening. Diabetes, Obesity and Metabolism, 2021, 23, 1331-1341.	4.7	2
43	Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report. Frontiers in Medicine, 2021, 8, .	2.6	2
44	Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future. Diabetes Therapy, 2021, 12, 2289-2310.	2.2	36
45	A fully implantable device for intraperitoneal drug delivery refilled by ingestible capsules. Science Robotics, 2021, 6, .	20.0	55
46	Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies. Diabetes Research and Clinical Practice, 2021, 180, 109066.	6.2	33
47	Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 896-907.	44.0	667
48	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology,the, 2021, 9, 653-662.	22.6	1,231
49	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes Care, 2021, 44, 774-780.	10.1	7
50	COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care, 2021, 44, 2645-2655.	10.1	260
51	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet, The, 2021, 398, 1811-1824.	52.0	525
52	Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. Current Medical Research and Opinion, 2020, 36, 555-562.	2.2	3
53	Reinterpreting Cardiorenal Protection of Renal Sodiumâ€“Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming. Diabetes Care, 2020, 43, 501-507.	10.1	48
54	Effects of treatment with metformin and/or sitagliptin on betaâ€cell function and insulin resistance in prediabetic women with previous gestational diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 648-657.	4.7	26

#	Article	IF	PR Citations
55	Type 1 diabetes and COVID-19: The â€œlockdown effectâ€• Diabetes Research and Clinical Practice, 2020, 170, 108468.	6.2	47
56	COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes and Endocrinology,the, 2020, 8, 782-792.	22.6	769
57	Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes Care, 2020, 43, 2345-2348.	10.1	150
58	Guida pratica alla prevenzione e gestione dellâ€™infezione da COVID-19 nelle persone con diabete. L Endocrinologo, 2020, 21, 241-245.	0.0	1
59	Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care, 2020, 43, e139-e141.	10.1	45
60	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. Diabetologia, 2020, 63, 2423-2433.	8.2	28
61	Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes and Endocrinology,the, 2020, 8, 640-648.	22.6	153
62	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. Diabetes Care, 2020, 43, 1065-1069.	10.1	21
63	Review of methods for detecting glycemic disorders. Diabetes Research and Clinical Practice, 2020, 165, 108233.	6.2	165
64	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. Diabetes Care, 2020, 43, 1695-1703.	10.1	174
65	Efficacy and safety of onceâ€•monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placeboâ€•controlled, 16â€•week randomized doseâ€•finding study. Diabetes, Obesity and Metabolism, 2020, 22, 1176-1186.	4.7	36
66	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology, 2020, 27, 1663-1674.	2.1	11
67	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovascular Diabetology, 2020, 19, .	9.9	27
68	Nesidioblastosis and Insulinoma: A Rare Coexistence and a Therapeutic Challenge. Frontiers in Endocrinology, 2020, 11, .	4.1	16
69	Plasma N-Acetylaspartate Is Related to Age, Obesity, and Glucose Metabolism: Effects of Antidiabetic Treatment and Bariatric Surgery. Frontiers in Endocrinology, 2020, 11, .	4.1	16
70	Impact of disease duration and Î²â€•cell reserve on the efficacy of switching to <scp>iGlarLixi</scp> in adults with type 2 diabetes on glucagonâ€•like peptideâ€•1 receptor agonist therapy: Exploratory analyses from the <scp>LixiLanâ€•G</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1567-1576.	4.7	11
71	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. Metabolism: Clinical and Experimental, 2020, 107, 154242.	9.5	21
72	Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 252-260.	4.7	37

#	Article	IF	PR Citations
73	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovascular Diabetology, 2019, 18, .	9.9	32
74	Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire. L Endocrinologo, 2019, 20, 336-340.	0.0	1
75	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes Care, 2019, 42, 2108-2116.	10.1	76
76	Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet, The, 2019, 394, 1519-1529.	52.0	303
77	Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3296-3302.	4.2	11
78	A preâ€specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. Diabetes, Obesity and Metabolism, 2019, 21, 2240-2247.	4.7	8
79	Exenatide modulates visual cortex responses. Diabetes/Metabolism Research and Reviews, 2019, 35, .	5.2	4
80	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diabetes and Vascular Disease Research, 2019, 16, 399-414.	2.9	45
81	Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people. Primary Care Diabetes, 2019, 13, 330-352.	2.0	37
82	Immune Checkpoint Blockade Antiâ€“PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome. Journal of the Endocrine Society, 2019, 3, 496-503.	0.2	57
83	Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. Cardiovascular Diabetology, 2019, 18, .	9.9	62
84	Altered Visual Plasticity in Morbidly Obese Subjects. IScience, 2019, 22, 206-213.	3.7	27
85	Freestyle Libre trend arrows for the management of adults with insulin-treated diabetes: A practical approach. Journal of Diabetes and Its Complications, 2019, 33, 6-12.	2.6	23
86	Sustained 52â€week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 883-892.	4.7	21
87	Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality. Journal of Diabetes and Its Complications, 2018, 32, 550-557.	2.6	17
88	Alirocumab vs usual lipidâ€lowering care as addâ€on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DMâ€DYSLIPIDEMIA randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1479-1489.	4.7	90
89	Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial. Journal of Diabetes Investigation, 2018, 9, 579-586.	2.9	13
90	Practical strategies for improving outcomes in <scp>T2DM</scp>: <scp>T</scp>he potential role of pioglitazone and <scp>DPP4</scp> inhibitors. Diabetes, Obesity and Metabolism, 2018, 20, 786-799.	4.7	19

#	Article	IF	PR Citations
91	Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucoseâ€¯â‰¥â€¯155â€¯mg/dl (8.6â€¯mmol/L). Diabetes Research and Clinical Practice, 2018, 146, 18-33.	6.2	94
92	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	52.0	1,540
93	Pre-pregnancy obesity, gestational diabetes or gestational weight gain: Which is the strongest predictor of pregnancy outcomes?. Diabetes Research and Clinical Practice, 2018, 144, 286-293.	6.2	39
94	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitusâ€"Rationale, design, and baseline characteristics. American Heart Journal, 2018, 203, 30-38.	3.0	81
95	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Atherosclerosis, 2018, 276, 124-130.	1.6	30
96	Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus. Cardiovascular Diabetology, 2018, 17, .	9.9	6
97	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes, Obesity and Metabolism, 2018, 20, 2532-2540.	4.7	162
98	Type 2 Diabetes Mellitus. From the start â€“ combination therapy. Diabetes Mellitus, 2018, 21, 386-394.	1.2	3
99	Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs, 2017, 77, 247-264.	9.5	30
100	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. Diabetes Care, 2017, 40, 813-820.	10.1	126
101	Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. Diabetologia, 2017, 60, 1102-1113.	8.2	44
102	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	22.6	266
103	Efficacy and safety of alirocumab in insulinâ€treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DMâ€INSULIN</scp> randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1781-1792.	4.7	129
104	Gender difference in diabetes related excess risk of cardiovascular events: When does the â€˜risk windowâ€™ open?. Journal of Diabetes and Its Complications, 2017, 31, 74-79.	2.6	17
105	A Fermented Whole Grain Prevents Lipopolysaccharidesâ€Induced Dysfunction in Human Endothelial Progenitor Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, .	4.7	34
106	Metabolic regulation of GLP-1 and PC1/3 in pancreatic Î±-cell line. PLoS ONE, 2017, 12, e0187836.	2.4	43
107	Ten Years of Vildagliptin. European Endocrinology, 2017, 13, 54.	2.6	0
108	Beliefs, Barriers, and Preferences of European Overweight Women to Adopt a Healthier Lifestyle in Pregnancy to Minimize Risk of Developing Gestational Diabetes Mellitus: An Explorative Study. Journal of Pregnancy, 2016, 2016, 1-11.	2.0	36

#	Article	IF	PR Citations
109	Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 886-892.	3.4	8
110	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care, 2016, 39, 861-877.	10.1	809
111	Integrating medical and surgical therapies to optimize the outcomes of type 2 diabetes. Surgery for Obesity and Related Diseases, 2016, 12, 1186-1191.	2.6	4
112	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care, 2016, 39, 717-725.	10.1	269
113	Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. Postgraduate Medicine, 2016, 128, 747-754.	2.8	6
114	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Surgery for Obesity and Related Diseases, 2016, 12, 1144-1162.	2.6	139
115	1h post-load blood glucose for detection of individuals at increased risk of diabetes and cardiovascular disease. Diabetes Research and Clinical Practice, 2016, 120, 184-185.	6.2	1
116	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovascular Diabetology, 2016, 15, .	9.9	47
117	Personalized Therapy by Phenotype and Genotype. Diabetes Care, 2016, 39, S127-S136.	10.1	16
118	Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Diabetes Care, 2016, 39, S113-S114.	10.1	4
119	Hospital incidental diagnosis of diabetes: A population study. Journal of Diabetes and Its Complications, 2016, 30, 457-461.	2.6	8
120	Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 361-373.	3.4	44
121	Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials. Primary Care Diabetes, 2016, 10, 51-59.	2.0	15
122	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations. Obesity Surgery, 2016, 27, 2-21.	2.7	139
123	Access to emergency room for hypoglycaemia in people with diabetes. Diabetes/Metabolism Research and Reviews, 2015, 31, 745-751.	5.2	15
124	Effect of diabetes on hospitalization for ischemic stroke and related inâ€hospital mortality: a study in Tuscany, Italy, over years 2004â€“2011. Diabetes/Metabolism Research and Reviews, 2015, 31, 280-286.	5.2	32
125	New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2015, 3, 638-652.	22.6	96
126	Gender difference in diabetes-associated risk of first-ever and recurrent ischemic stroke. Journal of Diabetes and Its Complications, 2015, 29, 713-717.	2.6	38

#	Article	IF	PR Citations
127	Progress and change. Journal of Diabetes and Its Complications, 2015, 29, 1.	2.6	1
128	Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 898-905.	3.4	63
129	Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146TCF7L2Gene Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1160-E1167.	4.2	16
130	The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. Journal of Diabetes and Its Complications, 2015, 29, 599-606.	2.6	18
131	Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. Diabetes Care, 2015, 38, 2293-2300.	10.1	46
132	Cardiovascular and heart failure safety profile of vildagliptin: a metaâ€analysis of 17â€‰000 patients. Diabetes, Obesity and Metabolism, 2015, 17, 1085-1092.	4.7	97
133	Physical activity, depressed mood and pregnancy worries in European obese pregnant women: results from the DALI study. BMC Pregnancy and Childbirth, 2015, 15, .	2.5	38
134	How much weight are women gaining during pregnancy? An Italian cohort study. Gynecological Endocrinology, 2015, 31, 942-944.	1.9	5
135	GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetologica, 2015, 52, 1129-1133.	2.7	16
136	Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetesâ€”The TOSCA.IT Study. European Journal of Nutrition, 2015, 55, 1645-1651.	3.6	53
137	Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor. Journal of Endocrinological Investigation, 2014, 7, 111-116.	3.1	0
138	Insulin receptors on circulating blood cells from patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects. Journal of Endocrinological Investigation, 2014, 10, 311-319.	3.1	7
139	High blood ketone body concentration in Type 2 non-insulin dependent diabetic patients. Journal of Endocrinological Investigation, 2014, 19, 99-105.	3.1	28
140	Left ventricular mass in type 2 diabetes mellitus. A study employing a simple ECG index: The Cornell voltage. Journal of Endocrinological Investigation, 2014, 23, 139-144.	3.1	3
141	Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. Journal of Endocrinological Investigation, 2014, 30, 610-614.	3.1	53
142	Gestational diabetes, inflammation, and late vascular disease. Journal of Endocrinological Investigation, 2014, 30, 873-879.	3.1	26
143	Pituitary autoimmunity in patients with diabetes mellitus and other endocrine disorders. Journal of Endocrinological Investigation, 2014, 36, 127-131.	3.1	9
144	Grain and Bean Lysates Improve Function of Endothelial Progenitor Cells from Human Peripheral Blood: Involvement of the Endogenous Antioxidant Defenses. PLoS ONE, 2014, 9, e109298.	2.4	31

#	Article	IF	PR Citations
145	Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499â€“1508. Diabetes Care, 2014, 37, e247-e247.	10.1	1
146	OP44 ORAL GLUCOSE LOWERING WITH LINAGLIPTIN PLUS METFORMIN COMPARED WITH LINAGLIPTIN ALONE AS INITIAL TREATMENT IN ASIAN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES AND MARKED HYPERGLYCEMIA. Diabetes Research and Clinical Practice, 2014, 106, S22-S23.	6.2	0
147	Cardiovascular risk assessment in low-resource settings. Journal of Hypertension, 2014, 32, 951-960.	2.3	82
148	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, The, 2014, 383, 1068-1083.	52.0	1,479
149	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care, 2014, 37, 2647-2659.	10.1	61
150	Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?. Diabetes Care, 2014, 37, 1499-1508.	10.1	146
151	Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. Vascular Health and Risk Management, 2014, , 465.	2.5	13
152	Q192R Paraoxonase (PON)1 Polymorphism, Insulin Sensitivity, and Endothelial Function in Essential Hypertensive Men. Clinical Medicine Insights: Cardiology, 2014, 8, CMC.S15493.	3.2	6
153	Insulin as an Early Treatment for Type 2 Diabetes. Diabetes Care, 2013, 36, S198-S204.	10.1	5
154	Personalized Management of Hyperglycemia in Type 2 Diabetes. Diabetes Care, 2013, 36, 1779-1788.	10.1	137
155	Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials. Journal of Diabetes and Its Complications, 2013, 27, 274-279.	2.6	17
156	Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?. Current Diabetes Reports, 2013, 13, 403-410.	5.5	44
157	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired Î²-Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2100-2105.	4.2	109
158	Vergleich von Dapagliflozin und Glipizid als Add-on-Therapie bei Typ-2-Diabetikern mit unzureichender Blutzuckerkontrolle unter Metformin. Deutsche Medizinische Wochenschrift, 2013, 138, S6-S16.	0.2	11
159	Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Diabetes Care, 2013, 36, S111-S112.	10.1	2
160	Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diabetes and Vascular Disease Research, 2013, 10, 397-409.	2.9	40
161	Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, , 161.	2.6	22
162	Early detection of left ventricular dysfunction in diabetes mellitus patients with normal ejection fraction, stratified by BMI: A preliminary speckle tracking echocardiography study. Journal of Cardiovascular Echography, 2013, 23, 73.	0.6	15

#	Article	IF	PR Citations
163	Measurement of Insulin Resistance In Vivo. Drugs, 2012, 58, 3-6.	9.5	6
164	Metabolic Syndrome. High Blood Pressure and Cardiovascular Prevention, 2012, 13, 185-198.	2.7	16
165	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. High Blood Pressure and Cardiovascular Prevention, 2012, 17, 73-102.	2.7	9
166	2009 SIPREC Consensus Document â€“ Executive Summary. High Blood Pressure and Cardiovascular Prevention, 2012, 17, 237-247.	2.7	0
167	1-Hour OGTT Plasma Glucose as a Marker of Progressive Deterioration of Insulin Secretion and Action in Pregnant Women. International Journal of Endocrinology, 2012, 2012, 1-5.	2.0	13
168	The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes. Diabetes Care, 2012, 35, e82-e82.	10.1	25
169	Evidence for a Role of Frataxin in Pancreatic Islets Isolated from Multi-Organ Donors with and Without Type 2 Diabetes Mellitus. Hormone and Metabolic Research, 2012, 44, 471-475.	1.9	12
170	Global Call for Free Academic Movement for International Dialogue. Diabetes Care, 2012, 35, 1631-1632.	10.1	1
171	Long-Term (5 Years) Efficacy and Safety of Pancreas Transplantation Alone in Type 1 Diabetic Patients. Transplantation, 2012, 93, 842-846.	1.1	46
172	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet, The, 2012, 379, 1498-1507.	52.0	314
173	Response Letter to D. Singhâ€Franco et al.. Diabetes, Obesity and Metabolism, 2012, 14, 1054-1055.	4.7	0
174	Telecare Provides Comparable Efficacy to Conventional Self-Monitored Blood Glucose in Patients with Type 2 Diabetes Titrating One Injection of Insulin Glulisineâ€"the ELEONOR Study. Diabetes Technology and Therapeutics, 2012, 14, 175-182.	5.2	49
175	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	2.1	5,448
176	Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 997-1006.	3.4	43
177	Pathogenetic Mechanisms and Cardiovascular Risk. Diabetes Care, 2012, 35, 2607-2612.	10.1	38
178	PPARG2 Pro12Ala and ADAMTS9 rs4607103 as â€œinsulin resistance lociâ€•and â€œinsulin secretion lociâ€•in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4. Acta Diabetologica, 2012, 50, 401-408.	2.7	34
179	Linagliptin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2011, 12, 2759-2762.	2.3	6
180	Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 699-705.	3.4	18

#	Article	IF	PR Citations
181	Management of type 2 diabetes: new and future developments in treatment. Lancet, The, 2011, 378, 182-197.	52.0	488
182	Results of Pancreas Transplantation Alone with Special Attention to Native Kidney Function and Proteinuria in Type 1 Diabetes Patients. Review of Diabetic Studies, 2011, 8, 259-267.	3.0	34
183	Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. Diabetes Care, 2011, 34, 2015-2022.	10.1	514
184	Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Diabetes Care, 2011, 34, S99-S100.	10.1	1
185	Multidrug Treatment of Type 2 Diabetes. Diabetes Care, 2011, 34, S231-S235.	10.1	43
186	Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study. Diabetes Care, 2011, 34, 2524-2526.	10.1	17
187	Metabolic Memory and Individual Treatment Aims in Type 2 Diabetes â€“ Outcome-Lessons Learned from Large Clinical Trials. Review of Diabetic Studies, 2011, 8, 432-440.	3.0	54
188	Blood Glucose Control and Coronary Heart Disease. Herz, 2010, 35, 148-159.	0.8	8
189	Serum gammaâ€glutamyltransferase levels are related to insulin sensitivity and secretion in subjects with abnormal glucose regulation. Diabetes/Metabolism Research and Reviews, 2010, 26, 181-186.	5.2	6
190	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes/Metabolism Research and Reviews, 2010, 26, 239-244.	5.2	106
191	Early Left Ventricular Mechanics Abnormalities in Prehypertension: A Two-Dimensional Strain Echocardiography Study. American Journal of Hypertension, 2010, 23, 405-412.	2.0	85
192	Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells. Microvascular Research, 2010, 80, 332-338.	2.6	47
193	G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: The role of type 2 diabetes and fatty acids. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 22-25.	3.4	59
194	A Common Polymorphism in the Monocyte Chemoattractant Protein-1 (MCP-1) Gene Regulatory Region Influences MCP-1 Expression and Function of Isolated Human Pancreatic Islets. Transplantation Proceedings, 2010, 42, 2247-2249.	0.7	10
195	Functional and Survival Analysis of Isolated Human Islets. Transplantation Proceedings, 2010, 42, 2250-2251.	0.7	7
196	P4.07 DIFFERENT IMPACT OF HYPERTENSION AND TYPE 2 DIABETES ON AORTIC, CAROTID AND PERIPHERAL VASCULAR STIFFNESS. Artery Research, 2010, 4, 162.	1.8	0
197	Physical activity and dietary habits during pregnancy: effects on glucose tolerance. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 1310-1314.	1.7	17
198	Changing the Treatment Paradigm for Type 2 Diabetes. Diabetes Care, 2009, 32, S217-S222.	10.1	36

#	Article	IF	PR Citations
199	Soluble CD40 Ligand Levels in Essential Hypertensive Men: Evidence of a Possible Role of Insulin Resistance. American Journal of Hypertension, 2009, 22, 1007-1013.	2.0	14
200	Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. Diabetes Care, 2009, 32, S342-S348.	10.1	27
201	How Do We Define Cure of Diabetes?. Diabetes Care, 2009, 32, 2133-2135.	10.1	916
202	Lack of association between TGF-Â-1 genotypes and microalbuminuria in essential hypertensive men. Nephrology Dialysis Transplantation, 2009, 24, 1864-1869.	0.8	11
203	Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 571-579.	3.4	40
204	The non-peptidyl low molecular weight radical scavenger IAC protects human pancreatic islets from lipotoxicity. Molecular and Cellular Endocrinology, 2009, 309, 63-66.	3.5	28
205	Serum gamma-glutamyltransferase is not associated to peripheral arterial disease in type 2 diabetic patients: Cross-sectional findings. Atherosclerosis, 2009, 203, 49-50.	1.6	2
206	Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia, 2008, 51, 615-622.	8.2	457
207	Î²-cell failure in type 2 diabetes mellitus. Current Diabetes Reports, 2008, 8, 179-184.	5.5	53
208	Optimizing management of metabolic syndrome to reduce risk: focus on life-style. Internal and Emergency Medicine, 2008, 3, 87-98.	3.2	27
209	Modulation of palmitic acidâ€induced cell death by ergothioneine: Evidence of an antiâ€inflammatory action. BioFactors, 2008, 33, 237-247.	5.5	49
210	Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 31-38.	3.4	17
211	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 624-631.	3.4	67
212	Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin. Atherosclerosis, 2008, 197, 346-354.	1.6	36
213	Î²-cell apoptosis in type 2 diabetes: quantitative and functional consequences. Diabetes and Metabolism, 2008, 34, S56-S64.	3.6	76
214	Primary Prevention of Cardiovascular Disease in People With Dysglycemia. Diabetes Care, 2008, 31, S208-S214.	10.1	43
215	Early Subclinical Atherosclerosis in Women With Previous Gestational Diabetes Mellitus. Diabetes Care, 2008, 31, e32-e32.	10.1	35
216	Metabolic Syndrome and Vascular Alterations in Normotensive Subjects at Risk of Diabetes Mellitus. Hypertension, 2008, 51, 440-445.	7.0	57

#	Article	IF	PR Citations
217	Peripheral wave reflection and endothelial function in untreated essential hypertensive patients with and without the metabolic syndrome. Journal of Hypertension, 2008, 26, 1216-1222.	2.3	22
218	Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile. Journal of Human Hypertension, 2008, 23, 332-338.	2.8	8
219	Coxsackie B4 virus infection of Î² cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5115-5120.	7.8	548
220	Treating the metabolic syndrome. Expert Review of Cardiovascular Therapy, 2007, 5, 491-506.	1.9	60
221	Cystatin C and Estimates of Renal Function: Searching for a Better Measure of Kidney Function in Diabetic Patients. Clinical Chemistry, 2007, 53, 480-488.	1.1	158
222	Maternal Metabolic Control and Perinatal Outcome in Women With Gestational Diabetes Mellitus Treated With Lispro or Aspart Insulin: Comparison with regular insulin. Diabetes Care, 2007, 30, e11-e11.	10.1	48
223	An Off-the-Shelf Instant Contact Casting Device for the Management of Diabetic Foot Ulcers: A randomized prospective trial versus traditional fiberglass cast. Diabetes Care, 2007, 30, 586-590.	10.1	115
224	Correspondence Between the International Diabetes Federation Criteria for Metabolic Syndrome and Insulin Resistance in a Cohort of Italian Nondiabetic Caucasians: The GISIR database. Diabetes Care, 2007, 30, e33-e33.	10.1	4
225	Normal Glucose Tolerance and Gestational Diabetes Mellitus: What is in between?. Diabetes Care, 2007, 30, 1783-1788.	10.1	70
226	Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men. Journal of Hypertension, 2007, 25, 1389-1395.	2.3	23
227	Evaluation ofÂmetalloproteinase 2Âand 9Âlevels andÂtheirÂinhibitors inÂdiabetic andÂhealthy subjects. Diabetes and Metabolism, 2007, 33, 129-134.	3.6	120
228	Insulin secretion defects ofÂhuman type 2Âdiabetic islets are corrected inÂvitro byÂaÂnew reactive oxygen species scavenger. Diabetes and Metabolism, 2007, 33, 340-345.	3.6	52
229	Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2007, 78, 246-253.	6.2	25
230	High insulin levels impair intracellular receptor trafficking in human cultured myoblasts. Diabetes Research and Clinical Practice, 2007, 78, 316-323.	6.2	12
231	Doxazosin in metabolically complicated hypertension. Expert Review of Cardiovascular Therapy, 2007, 5, 1027-1035.	1.9	9
232	When and how to restore Î²-cell function?. International Congress Series, 2007, 1303, 138-145.	0.2	2
233	Effects of C-peptide on isolated human pancreatic islet cells. Diabetes/Metabolism Research and Reviews, 2007, 23, 215-219.	5.2	19
234	ÃŸâ€cell function and antiâ€diabetic pharmacotherapy. Diabetes/Metabolism Research and Reviews, 2007, 23, 518-527.	5.2	71

#	Article	IF	PR Citations
235	Type 2 diabetes mellitus: focus on new treatments and special populations. International Journal of Clinical Practice, 2007, 61, 1-2.	2.1	3
236	Left Ventricular Function in Normotensive Young Adults With Well-Controlled Type 1 Diabetes Mellitus. American Journal of Cardiology, 2007, 99, 84-90.	1.9	47
237	Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. Journal of Diabetes and Its Complications, 2007, 21, 20-27.	2.6	16
238	Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia, 2007, 50, 2156-2163.	8.2	97
239	Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. Journal of Clinical Investigation, 2007, 117, 2155-2163.	9.0	725
240	We-P11:184 Endothelial nitric oxide synthase (ENOS) GLU298ASP and T-786C gene polymorphism and metabolic syndrome in essential hypertension. Atherosclerosis Supplements, 2006, 7, 386.	2.8	0
241	The metabolic syndrome. Pharmacological Research, 2006, 53, 457-468.	9.4	14
242	Early impairment of Î²-cell function and insulin sensitivity characterizes normotolerant Caucasian women with previous gestational diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 485-493.	3.4	9
243	Transcription factors of beta-cell differentiation and maturation in isolated human islets: Effects of high glucose, high free fatty acids and type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, e7-e8.	3.4	9
244	Tackling Hyperglycemia: A More Comprehensive Approach. Endocrine Practice, 2006, 12, 63-66.	3.5	28
245	Ace/Aace Consensus Conference on The Implementation of Outpatient Management of Diabetes Mellitus: Consensus Conference Recommendations. Endocrine Practice, 2006, 12, 6-12.	3.5	75
246	ACE gene insertion/deletion polymorphism modulates capillary permeability in hypertension. Clinical Science, 2006, 111, 357-364.	6.3	14
247	Inhaled insulins: the present and future of diabetes therapy. Current Medical Research and Opinion, 2006, 22, S13-S19.	2.2	6
248	Î±-Adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria. Journal of Hypertension, 2006, 24, 931-937.	2.3	17
249	Disappearance of Nephrotic Syndrome in Type 1 Diabetic Patients Following Pancreas Transplant Alone. Transplantation, 2006, 81, 1067-1068.	1.1	21
250	Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. Diabetologia, 2006, 49, 2977-2982.	8.2	111
251	Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transplantation, 2006, 12, 285-291.	2.6	57
252	The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coronary Artery Disease, 2005, 16, 67-73.	1.2	21

#	Article	IF	PR Citations
253	Unlocking the opportunity of tight glycaemic control. Far from goal. Diabetes, Obesity and Metabolism, 2005, 7, S1-S4.	4.7	7
254	Effects of pancreas-kidney transplantation on diabetic retinopathy. Transplant International, 2005, 18, 619-622.	2.1	92
255	Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. Journal of Diabetes and Its Complications, 2005, 19, 60-64.	2.6	74
256	Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia, 2005, 48, 282-289.	8.2	351
257	Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women. Diabetes Care, 2005, 28, 982-983.	10.1	48
258	Hepatitis C Virus Infection and Human Pancreatic Â-Cell Dysfunction. Diabetes Care, 2005, 28, 940-941.	10.1	115
259	The Beneficial Effects of Pancreas Transplant Alone on Diabetic Nephropathy. Diabetes Care, 2005, 28, 1366-1370.	10.1	91
260	Functional and Molecular Defects of Pancreatic Islets in Human Type 2 Diabetes. Diabetes, 2005, 54, 727-735.	0.5	437
261	Chlorthalidone Improves Endothelial-Mediated Vascular Responses in Hypertension Complicated by Nondiabetic Metabolic Syndrome. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, 265-272.	2.8	19
262	Ninety-Five Percent Insulin Independence Rate 3 Years After Pancreas Transplantation Alone With Portal-Enteric Drainage. Transplantation Proceedings, 2005, 37, 1274-1277.	0.7	13
263	Successful Solitary Pancreas Transplantation With Portal-Enteric Drainage Following Unsuccessful Islet Cell Transplantation. Transplantation Proceedings, 2005, 37, 1278-1279.	0.7	1
264	Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 250-254.	3.4	168
265	Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals. Pharmacological Research, 2005, 51, 561-565.	9.4	10
266	Continually high insulin levels impair Akt phosphorylation and glucose transport in human myoblasts. Metabolism: Clinical and Experimental, 2005, 54, 1687-1693.	9.5	41
267	Activation of the Hexosamine Pathway Leads to Phosphorylation of Insulin Receptor Substrate-1 on Ser307 and Ser612 and Impairs the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Insulin Biosynthetic Pathway in RIN Pancreatic Î²-Cells. Endocrinology, 2004, 145, 2845-2857.	2.6	66
268	Rosiglitazone plus metformin: combination therapy for Type 2 diabetes. Expert Opinion on Pharmacotherapy, 2004, 5, 1411-1422.	2.3	13
269	Targeting Insulin Resistance and Î²-Cell Dysfunction: The Role of Thiazolidinediones. Diabetes Technology and Therapeutics, 2004, 6, 719-731.	5.2	18
270	Pancreatic Islets from Type 2 Diabetic Patients Have Functional Defects and Increased Apoptosis That Are Ameliorated by Metformin. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5535-5541.	4.2	322

#	Article	IF	PR Citations
271	Exogenous and Endogenous Postprandial Lipid Abnormalities in Type 2 Diabetic Patients with Optimal Blood Glucose Control and Optimal Fasting Triglyceride Levels. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2153-2159.	4.2	87
272	Serum Haptoglobin: A Novel Marker of Adiposity in Humans. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2678-2683.	4.2	112
273	Insulin Resistance Is Independently Associated With Postprandial Alterations of Triglyceride-Rich Lipoproteins in Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2397-2402.	6.4	74
274	Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients. Nephrology Dialysis Transplantation, 2004, 19, 2419-2420.	0.8	2
275	Low-Grade Inflammation and Microalbuminuria in Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2414-2419.	6.4	94
276	A simplified technique for the en bloc procurement of abdominal organs that is suitable for pancreas and small-bowel transplantation. Surgery, 2004, 135, 629-641.	1.8	58
277	Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. Diabetes/Metabolism Research and Reviews, 2004, 20, 246-251.	5.2	25
278	Beta- and Alpha-Cell Dysfunction in Type 2 Diabetes. Hormone and Metabolic Research, 2004, 36, 775-781.	1.9	102
279	Pancreas transplant alone. Transplantation Proceedings, 2004, 36, 569-570.	0.7	10
280	Solitary pancreas transplantation: preliminary findings about early reduction of proteinuria in incipient or evident diabetic type I nephropathy. Transplantation Proceedings, 2004, 36, 591-596.	0.7	4
281	Kidney and pancreas transplants in Jehovah's witnesses: ethical and practical implications. Transplantation Proceedings, 2004, 36, 601-602.	0.7	19
282	An alternative and simple method to consistently prepare viable isolated human islets for clinical transplantation. Transplantation Proceedings, 2004, 36, 605-606.	0.7	6
283	Portal entericâ€“drained solitary pancreas transplantation without surveillance biopsy: is it safe?. Transplantation Proceedings, 2004, 36, 1090-1092.	0.7	5
284	Simultaneous pancreas-kidney transplantation is improved by living kidney donation program. Transplantation Proceedings, 2004, 36, 1061-1063.	0.7	2
285	Single-Center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous Pancreas-Kidney transplantation. Transplantation Proceedings, 2004, 36, 1064-1066.	0.7	7
286	Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome. Atherosclerosis, 2004, 172, 383-389.	1.6	63
287	PANCREAS PRESERVATION WITH UNIVERSITY OF WISCONSIN AND CELSIOR SOLUTIONS: A SINGLE-CENTER, PROSPECTIVE, RANDOMIZED PILOT STUDY. Transplantation, 2004, 77, 1186-1190.	1.1	73
288	Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARÎ³₂ in the modulation of insulin secretion. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E560-E567.	3.1	138

#	Article	IF	PR Citations
289	In situ protein Kinase C activity is increased in cultured fibroblasts from Type 1 diabetic patients with nephropathy. Diabetologia, 2003, 46, 524-530.	8.2	19
290	Hyperglycaemia and cardiovascular risk. Acta Diabetologica, 2003, 40, s362-s369.	2.7	16
291	Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetologica, 2003, 40, 20-27.	2.7	28
292	Identification of cathepsin K as a novel marker of adiposity in white adipose tissue. Journal of Cellular Physiology, 2003, 195, 309-321.	4.2	63
293	Elevated non-esterified fatty acids impair nitric oxide independent vasodilation, in humans: evidence for a role of inwardly rectifying potassium channels. Atherosclerosis, 2003, 169, 147-153.	1.6	27
294	Prevalence and risk factors for gestational diabetes assessed by universal screening. Diabetes Research and Clinical Practice, 2003, 62, 131-137.	6.2	159
295	Type 2 diabetes: simple, dual or multiple pathogenetic defects?. International Congress Series, 2003, 1253, 95-103.	0.2	0
296	Reducing insulin resistance with metformin: the evidence today. Diabetes and Metabolism, 2003, 29, 6S28-6S35.	3.6	222
297	A Common Polymorphism in the Promoter of UCP2 Contributes to the Variation in Insulin Secretion in Glucose-Tolerant Subjects. Diabetes, 2003, 52, 1280-1283.	0.5	125
298	Treatment of Patients Over 64 Years of Age With Type 2 Diabetes: Experience from nateglinide pooled database retrospective analysis. Diabetes Care, 2003, 26, 2075-2080.	10.1	58
299	Semiquantitative Analysis of the Histopathological Features of the Neuropathic Foot Ulcer: Effects of pressure relief. Diabetes Care, 2003, 26, 3123-3128.	10.1	118
300	Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. Journal of Hypertension, 2003, 21, 1163-1169.	2.3	11
301	Solitary pancreas transplantation in wolfram syndrome1.. Transplantation, 2003, 76, 1535.	1.1	4
302	Pancreas transplant alone determines early improvement of cardiovascular risk factors and cardiac function in type 1 diabetic patients1. Transplantation, 2003, 76, 974-976.	1.1	45
303	Prolonged Exposure to Free Fatty Acids Has Cytostatic and Pro-Apoptotic Effects on Human Pancreatic Islets. Diabetes, 2002, 51, 1437-1442.	0.5	563
304	Concomitance of Diabetic Retinopathy and Proteinuria Accelerates the Rate of Decline of Kidney Function in Type 2 Diabetic Patients. Diabetes Care, 2002, 25, 2026-2031.	10.1	56
305	Early Improvement of Unstable Diabetic Retinopathy After Solitary Pancreas Transplantation. Diabetes Care, 2002, 25, 2358-2359.	10.1	29
306	Insulin Secretory Function Is Impaired in Isolated Human Islets Carrying the Gly972->Arg IRS-1 Polymorphism. Diabetes, 2002, 51, 1419-1424.	0.5	104

#	Article	IF	PR Citations
307	Lipotoxicity in Human Pancreatic Islets and the Protective Effect of Metformin. Diabetes, 2002, 51, S134-S137.	0.5	161
308	Phasic Insulin Release and Metabolic Regulation in Type 2 Diabetes. Diabetes, 2002, 51, S109-S116.	0.5	194
309	Biochemical and ultrasound tests for early diagnosis of active neuro-osteoarthropathy (NOA) of the diabetic foot. Diabetes Research and Clinical Practice, 2002, 58, 1-9.	6.2	30
310	A telemedicine support for diabetes management: the T-IDDM project. Computer Methods and Programs in Biomedicine, 2002, 69, 147-161.	4.7	109
311	Universal screening and intensive metabolic management of gestational diabetes: cost-effectiveness in Italy. Acta Diabetologica, 2002, 39, 69-73.	2.7	27
312	In search of normoglycaemia in diabetes: controlling postprandial glucose. International Journal of Obesity, 2002, 26, S9-S17.	3.2	82
313	Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients. Diabetes Research and Clinical Practice, 2001, 51, 97-105.	6.2	15
314	Continuous subcutaneous insulin infusion in a patient with partial endocrine pancreatic graft function. Transplantation Proceedings, 2001, 33, 3500-3501.	0.7	0
315	Cardiovascular risk factors in recipients of successful kidney-pancreas transplantation. Transplantation Proceedings, 2001, 33, 3681.	0.7	0
316	Glucose intolerance and diabetes in recipients of kidney graft: comparison of old and new ADA and WHO criteria. Transplantation Proceedings, 2001, 33, 3664.	0.7	0
317	The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2001, 17, 164-174.	5.2	210
318	Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. International Journal of Obesity, 2000, 23, 1307-1313.	3.2	57
319	Brain function rescue effect of lactate following hypoglycaemia is not an adaptation process in both normal and Type I diabetic subjects. Diabetologia, 2000, 43, 733-741.	8.2	70
320	Mechanisms of acute and chronic hypoglycemic action of gliclazide. Acta Diabetologica, 2000, 37, 201-206.	2.7	11
321	Plasma Free Fatty Acids and Endothelium-Dependent Vasodilation: Effect of Chain-Length and Cyclooxygenase Inhibition. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 793-798.	4.2	64
322	Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance. Diabetologia, 1997, 40, 687-697.	8.2	88
323	Gliclazide potentiates suppression of hepatic glucose production in nonâ€"insulin-dependent diabetic patients. Metabolism: Clinical and Experimental, 1996, 45, 1196-1202.	9.5	15
324	Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals.. Journal of Clinical Investigation, 1996, 98, 108-115.	9.0	82

#	Article	IF	PR Citations
325	Unresectable hepatocellular carcinoma in cirrhosis. Digestive Diseases and Sciences, 1996, 41, 2332-2339.	2.3	72
326	Insulin resistance and diabetes mellitus. Journal of Diabetes and Its Complications, 1996, 10, 243-245.	2.6	37
327	Insulin Sensitivity Is Not Impaired In Mexican-American Women Without a Family History Of Diabetes. Diabetes Care, 1995, 18, 825-833.	10.1	9
328	What therapy do our NIDDM patients need? Insulin releasers. Diabetes Research and Clinical Practice, 1995, 28, S159-S165.	6.2	12
329	Improvement of Basal Hepatic Glucose Production ana Fasting Hyperglycemia of Type I Diabetic Patients Treated With Human Recombinant Ultralente Insulin. Diabetes Care, 1994, 17, 535-540.	10.1	4
330	Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia, 1994, 37, 1025-1035.	8.2	294
331	Mechanisms of fasting hypoglycemia and concomitant insulin resistance in insulinoma patients. Metabolism: Clinical and Experimental, 1993, 42, 24-29.	9.5	28
332	Body Composition Study in The Elderly: Comparison Between Tritium Dilution Method and Dual Photon Absorptiometry. Journal of Gerontology, 1993, 48, M244-M248.	2.8	9
333	Short-term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives. Journal of Hypertension, 1993, 11, S276???S277.	2.3	14
334	Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus.. Journal of Clinical Investigation, 1993, 91, 484-494.	9.0	161
335	Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes.. Journal of Clinical Investigation, 1993, 92, 486-494.	9.0	135
336	Retrospective analysis of daily glucose profile in type 1 diabetic patients with continuous subcutaneous insulin infusion (CSII). Diabetes Research and Clinical Practice, 1992, 16, 197-202.	6.2	2
337	The contribution of hyperglycaemia and hypoinsulinaemia to the insulin resistance of streptozotocin-diabetic rats. Diabetologia, 1992, 35, 310-315.	8.2	41
338	Rationale for the association of sulfonylurea and insulin. American Journal of Medicine, 1991, 90, S77-S82.	2.3	6
339	Glucose Turnover and Recycling in Diabetes Secondary to Total Pancreatectomy: Effect of Glucagon Infusion*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1023-1029.	4.2	22
340	Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in Type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents. Diabetologia, 1990, 33, 688-695.	8.2	25
341	Insulin regulation of glucose and lipid metabolism in massive obesity. Diabetologia, 1990, 33, 228-236.	8.2	58
342	Obesity and insulin resistance in humans: A dose-response study. Metabolism: Clinical and Experimental, 1990, 39, 452-459.	9.5	348

#	Article	IF	PR Citations
343	Metabolic control during total parenteral nutrition: Use of an artificial endocrine pancreas. Metabolism: Clinical and Experimental, 1988, 37, 510-513.	9.5	14
344	The combined treatment with insulin and sulfonylurea in non-insulin-dependent diabetic patients with secondary failure. Diabetes Research and Clinical Practice, 1988, 4, 75-81.	6.2	4
345	Hyperglucagonemia and insulin-mediated glucose metabolism.. Journal of Clinical Investigation, 1987, 79, 547-556.	9.0	86
346	Hyperalaninaemia is an early feature of diabetes secondary to total pancreatectomy. Diabetologia, 1985, 28, 277-281.	8.2	8
347	Effects of Insulin Treatment on Ketone Body Production and Carnitine-Palmitoyl-Transferase (CPT) Activity in the Isolated Perfused Liver from Streptozotocin Diabetic Rats. Hormone and Metabolic Research, 1985, 17, 271-274.	1.9	3
348	Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy. Diabetologia, 1983, 25, 252-259.	8.2	28
349	Metabolic effects of moderate alcohol intake with meals in insulin-dependent diabetics controlled by artificial endocrine pancreas (AEP) and in normal subjects. Metabolism: Clinical and Experimental, 1983, 32, 463-470.	9.5	17
350	The Presence of Retinopathy in Patients with Secondary Diabetes Following Pancreatectomy or Chronic Pancreatitis. Diabetes Care, 1983, 6, 570-574.	10.1	44
351	Insulin Resistance in Cushingâ€™s Syndrome*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 529-536.	4.2	146
352	The relationship between alanine and ketone body in vivo. Metabolism: Clinical and Experimental, 1982, 31, 1175-1178.	9.5	11
353	The antiketogenic effect of alanine in normal man: Evidence for an alanine-ketone body cycle. Metabolism: Clinical and Experimental, 1981, 30, 563-567.	9.5	24
354	Glycerophosphate acyltransferase activity in perfused liver of normal and hyperlipemic rats: Glucagon effect. Acta Diabetologica, 1981, 18, 357-363.	2.7	4
355	Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis. Acta Diabetologica Latina, 1980, 17, 111-118.	0.3	15
356	Continuous subcutaneous insulin infusion and multiple dose insulin injections in Type 1 diabetic pregnant women: a case-control study. Gynecological Endocrinology, 0, , 1-4.	1.9	10